PLSH
Panacea Life Sciences Holdings, Inc.0.0942
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.00MP/E (TTM)
-Basic EPS (TTM)
-0.36Dividend Yield
0%Recent Filings
8-K
Sky Wellness licensing deal
Panacea Life Sciences inked a licensing and supply deal with Sky Wellness on May 13, 2024, securing rights to market existing CBD inventory and develop new products like D Oh Gee dog chews and BoneUp male enhancement under the Sky Wellness brand. Panacea pockets 40% of net sales revenue. Sky Wellness vape products hit Tampa Pana Kava Java stores. Deal bolsters wellness lineup amid supply chain risks.
8-K
Dismisses tainted auditor BF Borgers
Panacea Life Sciences Holdings dismissed BF Borgers CPA PC as its independent auditor on May 6, 2024, after the firm lost SEC practice privileges on May 3. No audit disagreements or qualified opinions marred prior reports for 2022-2023, though material weaknesses persisted. Company plans quick replacement. Auditor switch disrupts filings.
10-Q
Q1 FY2024 results
Panacea Life Sciences boosted Q1 revenue 56% y/y to $1.1M from non-CBD nutraceutical contract manufacturing, while gross profit jumped to $666K on lower raw material costs—gross margin soared to 63%. Operating loss narrowed to $1.1M, yet net loss widened to $1.4M from higher interest expense on related-party debt. Cash edged up to $108K, with operating cash use at $357K offset by $369K related-party financing; free cash flow not disclosed in the 10-Q. Debt tops $20M, mostly related-party notes at 10-12%. Two customers drove 59% of sales. Customer concentration risks persist.
10-K
FY2023 results
Panacea Life Sciences Holdings posted FY2023 revenue of $2.4M, up 47% y/y from $1.6M, fueled by nutraceutical contract manufacturing and $0.6M from new Panacea Distro retail post-September acquisition, while PPE sales vanished. Yet operating losses widened to $5.5M amid 5% higher production costs and 33% G&A spike from bad debt write-offs including a $0.5M hit. Q4 momentum flickered via Distro integration, but cash burned $1.5M on operations, offset by $1.7M related-party notes; ending cash sat at $0.1M with $11.4M CEO debt. No guidance disclosed. Going concern wobbles.
8-K
Settles note via stock conversion
Panacea Life Sciences settled a $385,000 Senior Convertible Note on March 5, 2024, by converting the remaining $100,000 obligation into 666,000 common shares at $0.15 per share after missing the June 2023 cash deadline. It had already paid $135,000 on February 13, 2023, via CEO line of credit, and committed to converting 540,000 shares at $0.25. Cash crunch forced equity swap. Note now cleared.
IPO
Website
Employees
Sector
Industry
CBDL
CBD Life Sciences Inc.
0.00+0.00
CRLBF
Cresco Labs Inc.
1.75+0.45
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
CVSI
CV Sciences, Inc.
0.03+0.00
GSTK
Growth Stalk Holdings Corp
3.00+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
JUSHF
Jushi Holdings Inc.
0.84+0.11
KAYS
Kaya Holdings, Inc.
0.04+0.01
PHBI
Pharmagreen Biotech Inc.
0.00+0.00
PLNH
Planet 13 Holdings Inc.
0.30+0.06